Co-Diagnostics

$6.62 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Co-Diagnostics

Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

Stock Analysis

last close $6.33
1-mo return 5.9%
3-mo return 60.7%
avg daily vol. 766.12T
52-week high 11.82
52-week low 3.66
market cap. $230M
forward pe 14.1
annual div. -
roe 36.1%
ltg forecast -
dividend yield -
annual rev. $101M
inst own. 20.8%
baraka

Subscribe now for daily local and international financial news

Subscribe